Azora Therapeutics (@AzoraTx) header
Azora Therapeutics (@AzoraTx) profile picture

Developing potential best-in-class oral agonists of the aryl hydrocarbon receptor (AhR) agonists for ulcerative colitis.

Los Angeles
Joined February 2019
Adial Pharmaceuticals (NASDAQ: $ADIL) announced the acquisition of Azora Therapeutics and up to $64M PIPE. Supports Azora’s AT177, a proprietary colon-targeted AhR agonist designed to enable localized activation with limited systemic exposure. Read more: bit.ly/3SBbWvW
1
3
28
Azora Therapeutics retweeted
.@AdialPharma announced the acquisition of @AzoraTx, bringing AT177, a colon-targeted AhR agonist, into its pipeline. The transaction is supported by a concurrent private placement of up to $64M, including $32M upfront and potential additional milestone tranches. Adial will host a call and webcast today, June 11, 2026, at 1:00 pm ET to discuss the acquisition and financing. Dial-in: 1-877-451-6152 domestic / 1-201-389-0879 international; passcode 13761153. Webcast: bit.ly/4ejzOf5 Read more: bit.ly/3Q8x0cB $ADIL #Acquisition #PrivatePlacement #CorporateDevelopment
1
2
3
168